

HE RTS IN THE AMERICAS







CARDIOVASCULAR DISEASE AND COVID-19

Inter-relationship and opportunities for change of two global crises

Monday 16 November 2020 10:30 am - 12:30 pm (EST)

www.paho.org/en/hearts-americas





Late Breaking Journal Club Headlines

Jamario Skeete, MD Division of Cardiology Rush University Medical Center Chicago, IL







Integrated Blood Pressure Control

open access to scientific and medical research



REVIEW

Approaches to the Management of Hypertension in Resource-Limited Settings: Strategies to Overcome the Hypertension Crisis in the Post-COVID Era





IN THE AMERICAS

Integrated Blood Pressure Control

Dovepress

REVIEW

Approaches to the Management of Hypertension in **Resource-Limited Settings: Strategies to Overcome** the Hypertension Crisis in the Post-COVID Era

> This article was published in the following Dove Press journal: Integrated Blood Pressure Control

lamario Skeete Kenneth Connell 602 Pedro Ordunez Donald | DiPette⁴

Open Access Full Text Article

¹Division of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA; ²Faculty of Medical Sciences, University of the West Indies, Cave Hill Campus, St. Michael, Barbados; ³Department of Non-Communicable Diseases and Mental Health, Pan-American Health Organization, Washington, DC, USA; ⁴Department of Internal Medicine, University of South Carolina School of Medicine, University of South Carolina, Columbia SC USA

Correspondence: Jamario Skeete

Medical Center, 1717 W. Congress

Email Jamario_r_skeete@rush.edu

60612, USA

Tel +1 803-480-3275

Division of Cardiology, Department of Internal Medicine, Rush University

Parkway, Suite 317 Kellogg, Chicago, IL

Abstract: The COVID-19 pandemic has changed most aspects of everyday life in both the non-medical and medical settings. In the medical world, the pandemic has altered how healthcare is delivered and has necessitated an aggressive and new coordinated public health approach to limit its spread and reduce its disease burden and socioeconomic impact. This pandemic has resulted in a staggering morbidity and mortality and massive economic and physical hardships. Meanwhile, non-communicable diseases such as hypertension, diabetes mellitus, and cardiovascular disease in general continue to cause significant disease burden globally in the background. Though presently receiving less attention in the public eye than the COVID-19 pandemic, the hypertension crisis cannot be separated from the minds of healthcare providers, policymakers and the general public, as it continues to wreak havoc, particularly in vulnerable populations in resource limited settings. On this background, many of the strategies being employed to combat the COVID-19 pandemic can be used to reenergize and galvanize the fight against hypertension and hopefully bring the public health crisis associated with uncontrolled hypertension to an end.

Keywords: hypertension control, COVID-19 pandemic, resource-limited settings

Introduction

In 2020, through the Coronavirus (COVID-19) pandemic the world witnessed the devastating way disease can produce wide-scale death and suffering.¹ During the pandemic, almost every person globally was affected either by the virus itself or through the concurrent vast social and economic hardships produced in its wake.² In parallel, another global public health crisis has relentlessly continued in the background- the crisis of cardiovascular disease and its major risk factor, uncontrolled hypertension.³ Though more insidious in its onset when compared to COVID-19, the impact of cardiovascular disease is likewise, far reaching.

Though not a pandemic by strict definitions, cardiovascular disease is now reaching pandemic proportions and like the COVID-19 pandemic, calls for novel, aggressive and decisive public health action to "flatten" and "reverse" the curve of its current ascending trajectory.4-6 This is essential as, after decades of reductions in CVD premature mortality, a significant slowdown in this progress has been documented for the USA, and others high-income countries,7 a phenomena which is likely to be replicated in resource limited settings. To address this, every effort must be made to protect the gains already made and ultimately continue to reduce the cardiovascular disease burden.8

Paper aims


 Explore the overlap between the COVID-19 pandemic and the hypertension crisis

 Describe a framework for management of hypertension based on lessons learned from the response to the **COVID-19** pandemic






Hypertension Paradigm







Strategy to improved control







Hypertension Step 1 – Address Risk Factors Reduce your How to reduce the risks: salt intake Engage in regular physical activity Stop the spread. Save lives. PAHO Maintain a healthy weight CCVID-19 CORONAVIRUS Eat fresh natural foods Don't smoke Follow medical advice Pan American Health Organization World Health Organization #KnowYourNumbers Together we can overcome this public health emergency. www.paho.org





• Step 2 – Determine true prevalence











• Step 3 – Improve framework for standardized management Technical package for cardiovascular disease management in primary health care 9Þ Healthy-lifestyle counselling Ð **Evidence-based treatment protocols** Access to essential medicines and technology **Team-based care** -~~ Systems for monitoring World Health Organization www.who.int/cardiovascular diseases/hearts/en






 Step 4 – Improve cohort monitoring

<text>



Globally, only 1 of every 7 people has their hypertension under control







Main take-home points

Conclusion

The ongoing COVID-19 pandemic and the multiple lessons learned through this crisis, brings to the fore, many strategies that can be applied to the management of hypertension in low to middle-income countries. It also reminds us, of the need for a unified, multisector strategic approach, to not only identify the areas of deficiency to the existing management structure but more importantly, to develop meaningful solutions to likewise address this public health crisis. As such the formulation of programs that utilize a standardized and simplified approach to cardiovascular diseases management and cardiovascular risk factors, particularly the detection, treatment, and control of hypertension is likely to be essential going forward to address the increasing burden of hypertension, especially in resource-limited settings such as in LMICs. • The hypertension crisis is real, and highly destructive

• Like the COVID-19 pandemic, it needs decisive action

 Lessons leant should be applied promptly





ORIGINAL PAPER

Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative

Donald J. DiPette MD¹ I Kenneth Goughnour MPH, MCH² | Eric Zuniga MD³ | Jamario Skeete MD⁴ | Emily Ridley PharmD⁵ I Sonia Angell MD, MD, MPH⁶ | Jeffrey Brettler MD⁷ | Norm R. C. Campbell MD⁸ I Antionio Coca MD, PhD⁹ | Kenneth Connell MBBS, PhD¹⁰ | Rohit Doon MBBS, DPH, DIH¹¹ | Marc Jaffe MD¹² | Patricio Lopez-Jaramillo MD¹³ | Andrew Moran MD, MPH^{14,15} | Marcelo Orias MD, PhD¹⁶ | Daniel J. Pineiro MD¹⁷ | Andres Rosende MD¹⁸ | Yamilé Valdés González MD, MSc^{19,20} | Pedro Ordunez MD, PhD²¹





Paper aims

 To describe the adoption of the **Evidence Based protocols** (Module E) of the HEARTS of the **Americas Protocol**

ORIGINAL PAPER

WILEY

Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative

Donald J. DiPette MD¹ | Kenneth Goughnour MPH, MCH² | Eric Zuniga MD³ | Jamario Skeete MD⁴ | Emily Ridley PharmD⁵ | Sonia Angell MD, MD, MPH⁶ | Jeffrey Brettler MD⁷ | Norm R. C. Campbell MD⁸ | Antionio Coca MD, PhD⁹ Kenneth Connell MBBS, PhD¹⁰ | Rohit Doon MBBS, DPH, DIH¹¹ | Marc Jaffe MD¹² Patricio Lopez-Jaramillo MD¹³ | Andrew Moran MD, MPH^{14,15} | Marcelo Orias MD, PhD¹⁶ Daniel J. Pineiro MD¹⁷ | Andres Rosende MD¹⁸ | Yamilé Valdés González MD, MSc^{19,20} Pedro Ordunez MD. PhD²¹

¹School of Medicine, University of South Carolina, Columbia, SC, USA ²Women Influencing Health, Education and Rule of Law (WI-HER), Vienna, VA, USA ³ Health Service of Antofagasta, University of Antofagasta, Antofagasta, Chile *Department of Internal Medicine, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. ⁵ Prisma Health, Columbia, SC, USA ⁶ California Department of Public Health, California, IL, USA ⁷Kaiser Permanente Southern California, California, IL, USA * Department of Medicine, Physiology and Pharmacology and Community Health Sciences, O'Brien Institute for Public Health and Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada ⁹ Department of Internal Medicine, Hypertension and Vascular Risk Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain 10 Faculty of Medical Sciences, The University of the West Indies, St Michael, Barbados ¹¹ Ministry of Health, Port of Spain, Trinidad and Tobago 12 Division of Endocrinology, Kaiser Permanente, San Francisco, CA, USA ¹³ MASIRA Research Institute, Santander University (UDES), Bucaramanga, Colombia ³⁴ Resolve to Save Lives, An initiative of Vital Strategies, New York, NY, USA ¹⁵ Columbia University Irving Medical Center, New York, NY, USA 16 Sanatorio Allende Córdoba, Universidad Nacional de Córdoba, Cordoba, Argentina ¹⁷ Universidad de Buenos Aires, Buenos Aires, Argentina 18 National Ministry of Health, Buenos Aires, Argentina ³⁹ National Technical Advisory Commission on Hypertension, Havana, Cuba ²⁰ University Hospital "General Calixto Garcia" Havana, Cuba ²¹ Department of Non-Communicable Diseases and Mental Health, Pan American Health Organization, Washington, DC, USA

Correspondence

Donald J. DiPette MD, School of Medicine, University of South Carolina, Columbia, SC. USA. Email: donald.diPette@uscmed.sc.edu

Abstract

Funding information University South Carolina School of Medicine, Columbia, S.C., USA

Hypertension is the leading risk factor for cardiovascular disease (CVD) worldwide Despite the availability of effective antihypertensive medications, the control of hypertension at a global level is dismal, and consequently, the CVD burden continues to increase. In response, countries in Latin America and the Caribbean are implementing

© 2020 Wiley Periodicals LLC. The Pan American Health Organization (PAHO) retains copyright and all other rights in the manuscript of this article as submitted for publication

J Clin Hypertens, 2020;00:1-11






Ideal Characteristics of antihypertensive medications

- High efficacy
- Additive / synergistic BP reduction when used in combination
- Supported by clinical trials
- Limited side effects
- Affordable
- Available
- Easily titrated





Steps to building a hypertension protocol



• RAAS blocker, CCB, Diuretic

Step 1

Step 2

• Determine agents available in each class

 Build treatment algorithm using drugs within each class with ideal characteristics

Step 3





Shifting to a preferred protocol

Current Protocol What is being done right now Acceptable protocol Improved management using drugs already available on drug formulary Preferred protocol

Best standard of practice. May require modifying drug formulary to acquire most efficacious antihypertensive agents





Example of shift from current to preferred protocol


Step 1 (once the diagnosis of hypertension has been made)

Losartan 50 mg and amlodipine 5 mg

Step 2 (titration, if warranted)

Losartan 100 mg and amlodipine 10 mg

Step 3 (titration, if warranted)



Step 4 (titration, if warranted)

Losartan 100 mg and amlodipine 10 mg and hydrochlorothiazide 50 mg

Step 5 (if blood pressure not at control level)

Start a fourth medication or refer to specialist

Step 1 (once the diagnosis of hypertension has been made)

Telmisartan 40 mg and amlodipine 5 mg (in a FDC preparation and once daily)

Step 2 (titration, if warranted)

Telmisartan 80 mg and amlodipine 10 mg

Step 3 (titration, if warranted)

Telmisartan 80 mg and amlodipine 10 mg and chlorthalidone 12.5 mg

Step 4 (titration, if warranted)

Telmisartan 80 mg and amlodipine 10 mg and chlorthalidone 25 mg

Step 5 (if blood pressure not at control level)

Start a fourth medication or refer to specialist





Main take home points

8 | CONCLUSIONS

In conclusion, there are significant opportunities for improving hypertension control globally, including the diligent implementation of a standardized and comprehensive approach to hypertension treatment and control, such as Global HEARTS. A central and critical approach is designing and implementing a standardized treatment protocol pillar and securing the availability and affordability of highquality antihypertensive medications, thus leaving no one behind. The HEARTS in the Americas Initiative is an example of a standardized and innovative approach to hypertension control that is being replicated in other world regions. Training and program development practices and lessons learned by HEARTS in the Americas will continue to serve as a model for other regions worldwide to catalyze the actions needed to improve hypertension control and ultimately reduce the disease burden of CVD. Using a step-wise approach a hypertension protocol could be implemented building on existing medications available and transitioning to ideal medications with time.





Questions?

